Compare Abeona Therapeutics Inc (ABEO) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs MINISO Group Holding Ltd — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while MINISO Group Holding Ltd trades at $11.8 (market cap $3.52B). The key difference: MINISO Group Holding Ltd is far larger — about 9.4× Abeona Therapeutics Inc's market cap, and MINISO Group Holding Ltd pays a 5.69% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MNSO | |
|---|---|---|
Market Cap | $373.32M | $3.52B |
Sector | Health | Technology |
52-Week High | $7.23 | $26.63 |
52-Week Low | $4.17 | $11.30 |
Enterprise Value | $228.22M | $4.19B |
Dividend Yield | — | 5.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
MNSO trades at $11.90, up 1.54% today, with a bearish technical signal from moving averages and mixed oscillators. The company reported strong Q1 2026 earnings that beat expectations, with revenue growth of 28.5% year-over-year, and announced a HK$2 billion share repurchase program on June 29, 2026. Valuation ratios appear reasonable with a P/E of 12.11 and P/S of 1.1, while profitability metrics show a net income margin of 8.98% and ROE of 18.88%.
The outlook is cautiously optimistic given earnings momentum and shareholder-friendly actions, but risks include margin pressure from rising expenses and competitive threats. Analyst sentiment is positive with 75% buy ratings, though technical indicators suggest near-term resistance. Investors should weigh solid fundamentals against bearish price trends for entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
